Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Intracutaneous Drug Delivery Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of GENEVAX-HIV, a Possible Vaccine

NCT00002232
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
APL 400-003
Biological
Lead sponsor
Wyeth-Lederle Vaccines
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 6:34 PM EDT
Completed Not applicable Interventional Results available

Biolinq Safety and Effectiveness Trial

NCT06229743
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus
Interventions
Biolinq System
Device
Lead sponsor
Biolinq Inc.
Industry
Eligibility
22 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
6
States / cities
Escondido, California • Walnut Creek, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jul 22, 2026, 6:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

NCT01737710
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Fluzone® Intradermal Vaccine, Fluzone® (Intramuscular) vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years · Female only
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Jul 22, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of dmLT ID Vaccination in Healthy Adults

NCT02531685
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2020 · Synced Jul 22, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route

NCT00614731
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
KLH carrier-protein
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Jul 22, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of the Derma Vax(Trademark) Clinical Intradermal Electroporation System in Healthy Subjects

NCT01324843
View directory record Official record
Conditions
Intradermal Electroporation
Interventions
EMLA Cream, Aveeno Daily Moist, Derma Vax, Intradermal Electroporation, Visual Analogue Scale, Present Pain Intensity, McGill Pain Questionnaire, Skin Assessment
Drug · Device · Procedure
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 6:34 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin and Glucagon Delivery in Type 1 Diabetes

NCT01684956
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Intradermal injection, Subcutaneous injection
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 6, 2016 · Synced Jul 22, 2026, 6:34 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults

NCT00013572
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
ALVAC-HIV MN120TMG (vCP205)
Biological
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 6:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®

NCT00850603
View directory record Official record
Conditions
Meningococcal Infections, Meningitis
Interventions
Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
East Stroudsburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jul 22, 2026, 6:34 PM EDT
Completed Phase 1 Interventional

A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells

NCT00000667
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 22, 2026, 6:34 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine

NCT03282227
View directory record Official record
Conditions
Migraine
Interventions
M207 Microneedle System
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Jul 22, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)

NCT01689363
View directory record Official record
Conditions
Allergic Skin Reaction
Interventions
Hyaluronidase, Histamine, Saline
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
253 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
5
States / cities
Eugene, Oregon • Lake Oswego, Oregon • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Jul 22, 2026, 6:34 PM EDT
Completed Phase 1 Interventional

A Comparison Study of Prototype Continuous Glucose Sensors in the Intradermal and Subcutaneous Spaces

NCT01093833
View directory record Official record
Conditions
Diabetes
Interventions
BD Continuous glucose monitor (BD CGM), YSI Glucose Analyzer, Medtronic Guardian CGM
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Jul 22, 2026, 6:34 PM EDT
Not yet recruiting Phase 2 Interventional

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

NCT07634094
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib, Debulking Procedure
Drug · Biological · Procedure
Lead sponsor
Kalinski, Pawel, MD, PhD
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 22, 2026, 6:34 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

NCT03755713
View directory record Official record
Conditions
Peanut Allergy
Interventions
ASP0892, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Little Rock, Arkansas • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Jul 22, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available

Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis

NCT00928447
View directory record Official record
Conditions
Dermatitis, Allergic Contact
Interventions
rHuPH20, Placebo
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Michigan City, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Jul 22, 2026, 6:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pediatric Optimization of the PharmaJet Needle-Free Intradermal Delivery System

NCT01494571
View directory record Official record
Conditions
Functionality and Performance of Device
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Months to 14 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Jul 22, 2026, 6:34 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT

NCT05327426
View directory record Official record
Conditions
Poliomyelitis
Interventions
Intradermal fractional dose inactivated polio vaccine (fIPV) in combination with recombinant double mutant heat labile toxin, LT(R192G/L211A), (dmLT), Intradermal fractional dose inactivated polio vaccine (fIPV), Monovalent oral poliomyelitis vaccine (mOPV), Sabin strain
Biological
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Jul 22, 2026, 6:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device

NCT02146781
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control
Biological · Other
Lead sponsor
Immunomic Therapeutics, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Jul 22, 2026, 6:34 PM EDT
Completed Phase 1 Interventional

A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen

NCT00000782
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (Immuno-AG), gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
4
States / cities
Palo Alto, California • San Jose, California • San Mateo, California + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 22, 2026, 6:34 PM EDT
Completed Not applicable Interventional

Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection

NCT00000955
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Tuberculin Purified Protein Derivative
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
14
States / cities
New Haven, Connecticut • Wilmington, Delaware • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Jul 22, 2026, 6:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intracutaneous Delivery of Varied Dose Volumes of Saline

NCT01767337
View directory record Official record
Conditions
Influenza
Interventions
FLUGEN 101.2 device
Device
Lead sponsor
FluGen Inc
Industry
Eligibility
18 Years to 49 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Jul 22, 2026, 6:34 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes

NCT06919796
View directory record Official record
Conditions
Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2
Interventions
COMIRNATY®
Biological
Lead sponsor
PharmaJet, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Jul 22, 2026, 6:34 PM EDT
Completed Phase 1 Interventional

Phase I Study of Vaccination Schedule of Experimental HIV Vaccines

NCT00321061
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA016-00, VRC-HIVADV014-00
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 6:34 PM EDT